CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas
Cancer Chemotherapy and Pharmacology · 17.09.2026 · 96 (1)
DOI: 10.1007/s00280-026-04950-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 17.09.2026. Verfasst von Leire Balaguer-Lluna und 26 weiteren Autor:innen. Beteiligte Einrichtung: SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, 08950, Spain. Hauptthemen laut MEDLINE: Glioma, Proto-Oncogene Proteins c-akt, Phosphoinositide-3 Kinase Inhibitors, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundació Institució dels Centres de Recerca de Catalunya.
Abstract (Originalsprache)
Purpose
Pediatric-type diffuse high-grade gliomas (pHGG) are aggressive, largely incurable malignancies often characterized by PI3K/AKT pathway activation. This study investigated whether the PI3K inhibitor inavolisib and the AKT inhibitor ipatasertib could achieve therapeutic concentrations in the central nervous system (CNS) and demonstrate efficacy against PIK3CA -mutated pHGG.
Methods
A panel of 12 pHGG cell lines with diverse PI3K/AKT genetic aberrations was screened for sensitivity to inavolisib and ipatasertib. Pharmacokinetic (PK) modeling was performed in mice to determine brain-to-plasma exposure ratios following oral administration (50 mg/kg inavolisib and 100 mg/kg ipatasertib). Finally, the in vivo efficacy of both inhibitors was evaluated using intracranial PIK3CA -mutated pHGG xenograft models, with survival and cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) levels as primary endpoints.
Results
All 12 cell lines exhibited PI3K/AKT alterations. The PIK3CA H1047R-mutated line (HSJD-DIPG-007) was the most sensitive in vitro (IC 50 = 0.016 µM for inavolisib; 0.52 µM for ipatasertib). PK modeling revealed geometric mean brain-to-plasma ratios of 0.07 for inavolisib and 0.20 for ipatasertib, with model-predicted maximum brain concentrations of 0.69 µM and 0.93 µM, respectively. In vivo, inavolisib significantly extended survival ( P = 0.0070) and increased CSF ctDNA release ( P = 0.0317). In contrast, ipatasertib did not demonstrate significant in vivo activity.
Conclusion
These findings highlight the therapeutic potential of inavolisib for treating PIK3CA -mutated pHGG. Despite the blood-brain barrier, inavolisib achieved sufficient CNS exposure to prolong survival in preclinical models, whereas ipatasertib efficacy did not translate from in vitro to in vivo settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, 08950, Spain.
- Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
- Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, 1245, Argentina.
- National Scientific and Technical Research Council, CONICET, Buenos Aires, 1425, Argentina.
- Department of Analytical Chemistry, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, 01006, Spain.
- Hoffman-La Roche, Basel, 4058, Switzerland.
ORCID-Profile: Angel M Carcaboso
Förderung
- Fundació Institució dels Centres de Recerca de Catalunya
Zitieren
APA
Balaguer-Lluna, L., Resa-Parés, C., Brstilo, L., Gómez-Caballero, A., Baulenas-Farrés, M., Mohr, J., Hu, Y., Aschero, R., Rodríguez, A., Botteri, G., Rodríguez, E., Li-Chen, L., Mañogil, R., Marino, F., Martínez-Velasco, N., Ruano, A., García-Pelayo, Á., Giron, A., Mora, J., …, & Carcaboso, A. M. (2026). CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04950-5
Vancouver
Balaguer-Lluna L, Resa-Parés C, Brstilo L, Gómez-Caballero A, Baulenas-Farrés M, Mohr J, et al. CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04950-5
BibTeX
@article{BalaguerLluna2026,
author = {Balaguer-Lluna, Leire and Resa-Parés, Clàudia and Brstilo, Lucas and Gómez-Caballero, Alberto and Baulenas-Farrés, Mercè and Mohr, Jacqueline and Hu, Yutian and Aschero, Rosario and Rodríguez, Ana and Botteri, Gaia and Rodríguez, Eva and Li-Chen, Lydia and Mañogil, Raúl and Marino, Federica and Martínez-Velasco, Nuria and Ruano, Alex and García-Pelayo, Ángela and Giron, Auriane and Mora, Jaume and Lavarino, Cinzia and Sánchez-Navarro, Macarena and Teixidó, Meritxell and Ormazabal, Aida and Artuch, Rafael and Unceta, Nora and Schaiquevich, Paula and Carcaboso, Angel M},
title = {CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04950-5}
}
EUVIMED